Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Zyrexindo Mandiri Buana PT Tbk
IDX:ZYRX
|
ID |
|
N
|
Nanjing Well Pharmaceutical Co Ltd
SSE:603351
|
CN |
|
China Wuyi Co Ltd
SZSE:000797
|
CN |
Clinuvel Pharmaceuticals Ltd
Total Equity
Clinuvel Pharmaceuticals Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Equity
AU$249m
|
CAGR 3-Years
21%
|
CAGR 5-Years
26%
|
CAGR 10-Years
40%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Equity
$574.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
CSL Ltd
ASX:CSL
|
Total Equity
$18.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Equity
AU$23.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Equity
AU$415.4m
|
CAGR 3-Years
73%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Equity
AU$147.2m
|
CAGR 3-Years
87%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Total Equity?
Total Equity
249m
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Total Equity amounts to 249m AUD.
What is Clinuvel Pharmaceuticals Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
40%
Over the last year, the Total Equity growth was 15%. The average annual Total Equity growth rates for Clinuvel Pharmaceuticals Ltd have been 21% over the past three years , 26% over the past five years , and 40% over the past ten years .
